UPLOAD Filing
NewcelX Ltd.
Date: Sept. 29, 2025 · CIK: 0001783036 · Accession: 0000000000-25-010615
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290516
Letter
Re: NLS Pharmaceutics Ltd. Registration Statement on Form F-1 Filed September 25, 2025 File No. 333-290516 Dear Alexander Zwyer:
September 29, 2025
Alexander Zwyer Chief Executive Officer NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ron Ben-Bassat, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 29, 2025 Alexander Zwyer Chief Executive Officer NLS Pharmaceutics Ltd. The Circle 6 8058 Zurich, Switzerland Re: NLS Pharmaceutics Ltd. Registration Statement on Form F-1 Filed September 25, 2025 File No. 333-290516 Dear Alexander Zwyer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ron Ben-Bassat, Esq. </TEXT> </DOCUMENT>